28997
document
[ A randomized trial of PVB , VAB-6 , BVP regimen versus PEB chemotherapy in patients with disseminated testicular tumors ] . During 2 years and 7 months from June , 1985 to December , 1987 , a randomized multi-center trial of PVB , VAB-6 , BVP regimen ( group A ) without etoposide versus PEB chemotherapy ( bleomycin , etoposide and cisplatinum ) ( group B ) was given to patients with disseminated testicular tumors . Of 34 patients registered , 10 patients were with minimal disease in stages IIA , IIIO and IIIA and 24 with extensive disease in IIB , IIIB2 and IIIC . Seminomas were found in 10 patients , while non-seminomatous tumors in 24 . Among groups A and B , there was no statistical difference in clinicopathological profiles . A group patients were given either PVB , VAB-6 or BVP according to the physician 's discretion . In groups A and B , 35 % and 43 % of the patients achieved complete response , and 45 % and 50 % achieved partial response , respectively . The difference in CR rates among both groups was not statistically significant even when calculated according to the stage or histologic grouping . Salvage treatments mainly with surgical resection of residual tumors after the chemotherapy , however , were more successful in group B ( 88 % ) than group A ( 61 % ) . It appears likely that the higher response of induction chemotherapy in patients with extensive disease made the salvage surgery more successful in group B than in group A . The 3 year survival rate was 100 % in group B , whereas it was 76 % in group A . Although the incidence of myelosuppression and alopecia was significantly higher in group B , neuropathy was significantly more frequent in group A . From the above results , PEB seems to be a better induction chemotherapy than the conventional one for advanced testicular tumors .
28998
Intervention_Pharmacological
PVB , VAB-6 , BVP regimen versus PEB chemotherapy
28999
Intervention_Pharmacological
PVB , VAB-6 , BVP regimen
29000
Intervention_Pharmacological
etoposide
29001
Intervention_Pharmacological
PEB chemotherapy ( bleomycin , etoposide and cisplatinum )
29002
Intervention_Pharmacological
chemotherapy
29003
Intervention_Surgical
surgery
29004
Outcome_Physical
complete response
29005
Outcome_Physical
partial response
29006
Outcome_Mortality
3 year survival rate
29007
Outcome_Adverse-effects
incidence of myelosuppression and alopecia
29008
Outcome_Adverse-effects
neuropathy